Finally, TIL therapy is under early investigation in sarcomas; in this modality, autologous TILs are collected from an individual patient’s tumor and then expanded, and then returned to the patient with lymphodepleting chemotherapy and interleukin-2 (IL-2) therapy. The gene discussed is IL2; the disease is sarcoma.